We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+77.63%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$190M
Cap. Flow
+$101M
Cap. Flow %
17.32%
Top 10 Hldgs %
39.55%
Holding
201
New
71
Increased
49
Reduced
24
Closed
56

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.1M
2
CORT icon
Corcept Therapeutics
CORT
+$7.65M
3
VKTX icon
Viking Therapeutics
VKTX
+$5.07M
4
UTHR icon
United Therapeutics
UTHR
+$4.66M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.59M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
PCVX icon
Vaxcyte
PCVX
+$8.74M
3
SLNO
Soleno Therapeutics
SLNO
+$8.25M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$7.23M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 28.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTHS
101
Pelthos Therapeutics
PTHS
$94M
$775K 0.13%
25,000
+14,502
+138% +$418K
LQDA icon
102
Liquidia Corp
LQDA
$7.41B
$755K 0.13%
+21,881
New +$623K
EWTX icon
103
Edgewise Therapeutics
EWTX
$4.09B
$744K 0.13%
+30,000
New +$602K
VRDN icon
104
Viridian Therapeutics
VRDN
$2.07B
$657K 0.11%
+21,114
New +$579K
EDIT icon
105
CALL
Editas Medicine
EDIT
$402M
$653K 0.11%
318,700
+18,700
+6% +$54K
MLTX icon
106
CALL
MoonLake Immunotherapeutics
MLTX
$1.49B
$622K 0.11%
47,200
+21,100
+81% +$249K
INDV icon
107
Indivior Pharmaceuticals
INDV
$4.6B
$621K 0.11%
17,320
-236,932
-93% -$7.23M
VIR icon
108
Vir Biotechnology
VIR
$1.48B
$603K 0.1%
+100,000
New +$595K
LGND icon
109
Ligand Pharmaceuticals
LGND
$5.79B
$565K 0.1%
+2,987
New +$574K
ZYME icon
110
PUT
Zymeworks
ZYME
$1.62B
$563K 0.1%
+21,400
New +$467K
UPB
111
Upstream Bio Inc
UPB
$347M
$557K 0.1%
+20,500
New +$510K
STOK icon
112
Stoke Therapeutics
STOK
$1.82B
$545K 0.09%
+17,181
New +$516K
EQ icon
113
Equillium
EQ
$138M
$538K 0.09%
347,393
+47,393
+16% +$57.7K
VIR icon
114
CALL
Vir Biotechnology
VIR
$1.48B
$538K 0.09%
+89,200
New +$531K
CNTA
115
CALL
DELISTED
Centessa Pharmaceuticals
CNTA
$528K 0.09%
+21,100
New +$534K
URGN icon
116
UroGen Pharma
URGN
$1.88B
$511K 0.09%
21,810
-68,190
-76% -$1.48M
AVXL icon
117
CALL
Anavex Life Sciences
AVXL
$271M
$501K 0.09%
140,600
+800
+0.6% +$4.9K
IMNM icon
118
Immunome
IMNM
$2.6B
$483K 0.08%
+22,500
New +$395K
BDTX icon
119
CALL
Black Diamond Therapeutics
BDTX
$97.4M
$463K 0.08%
+190,400
New +$674K
JANX icon
120
CALL
Janux Therapeutics
JANX
$942M
$414K 0.07%
+30,000
New +$706K
CRVS icon
121
PUT
Corvus Pharmaceuticals
CRVS
$1.13B
$409K 0.07%
53,100
+3,100
+6% +$24.4K
PALI icon
122
Palisade Bio
PALI
$339M
$390K 0.07%
+166,049
New +$319K
PRQR icon
123
ProQR Therapeutics
PRQR
$243M
$338K 0.06%
167,532
+9,838
+6% +$23K
BIOA
124
CALL
BioAge Labs
BIOA
$463M
$299K 0.05%
+22,600
New +$200K
HRMY icon
125
Harmony Biosciences
HRMY
$2.04B
$281K 0.05%
7,500
-42,500
-85% -$1.4M
3 4
5
6 7

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Diadema Partners held 201 positions worth $581M, up 48% from $391M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Diadema Partners deployed $101M of net new capital in Q4 2025, opening 71 new positions and adding to 49 existing holdings. Its largest new stake was Johnson & Johnson: 66,444 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 37% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $13.5M trimmed.

  • Diadema Partners's largest Q4 2025 buy was Johnson & Johnson: 66,444 shares worth $13.8M.
  • Diadema Partners added most to Viking Therapeutics in Q4 2025, an estimated $5.07M increase.
  • Diadema Partners's biggest Q4 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $5.86M.
  • Diadema Partners's ten largest holdings make up 40% of its $581M portfolio in Q4 2025.
  • Diadema Partners opened 71 new positions and closed 56 in Q4 2025.
  • Diadema Partners's portfolio value rose 48% quarter-over-quarter to $581M.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.